Literature DB >> 10233419

Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study.

J C Byrd1, L H McGrail, D R Hospenthal, R S Howard, N A Dow, L F Diehl.   

Abstract

We performed a prospective infectious natural history study of 21 patients with low-grade lymphoproliferative disorders receiving fludarabine as initial (n = 5) or salvage (n = 16) therapy. 12 (57%) of these patients developed herpes zoster (n = 9), herpes simplex I (n = 1) or herpes simplex II (n = 2) infections at a median of 8 (range 1-17) months following initiation of fludarabine, with 75% of these having completed therapy. All patients with herpes zoster developed severe post-herpetic neuralgia. Factors differentiating patients developing these infections included older age and low serum IgG or IgA. Based upon these prospective data, we conclude that herpes virus infections frequently occur following fludarabine treatment, necessitating aggressive patient education and new prophylactic strategies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233419

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

Review 1.  Does rituximab increase the incidence of infectious complications? A narrative review.

Authors:  Theodoros Kelesidis; George Daikos; Dimitrios Boumpas; Sotirios Tsiodras
Journal:  Int J Infect Dis       Date:  2010-11-11       Impact factor: 3.623

2.  Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.

Authors:  Carla Casulo; Jocelyn Maragulia; Andrew D Zelenetz
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-12-29

3.  Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Jan A Burger; Kristie A Blum; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Yun Shaw; Elizabeth Bilotti; Cathy Zhou; Danelle F James; Susan O'Brien
Journal:  Blood       Date:  2015-02-19       Impact factor: 22.113

4.  Herpes Zoster Risk in Immunocompromised Adults in the United States: A Systematic Review.

Authors:  Susannah L McKay; Angela Guo; Steven A Pergam; Kathleen Dooling
Journal:  Clin Infect Dis       Date:  2020-10-23       Impact factor: 9.079

5.  Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia.

Authors:  Wenjun Zhang; Yi Ding; Hao Wu; Yuhua Chen; Huina Lu; Chunying Chen; Jianfei Fu; Weiguang Wang; Aibin Liang; Shanhua Zou
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.